This clinical trial focuses on patients with Low-grade Upper Tract Urothelial Cancer, a type of cancer that develops in the lining of the kidney’s collecting system. The study will test a new medicine called UGN-104, which contains the active substance mitomycin. This treatment comes in the form of a powder that is mixed into a solution before use.
The purpose of this research is to evaluate how effective UGN-104 is at removing tumors in patients with this type of cancer. The medication will be given directly into the upper urinary tract through a procedure called intravesical administration. Each patient will receive six treatments of the medicine over a treatment period that can last up to 12 months.
After completing the treatment, patients will have a check-up approximately 5 weeks after their final dose to determine if the treatment was successful in eliminating the cancer. The study will continue to monitor patients to see how long the treatment effects last and to check for any side effects. Throughout the study, doctors will perform various tests to ensure patient safety, including blood tests and imaging of the urinary tract.
Bulgaria 
Hungary 
Latvia 
Poland 
Romania 
Spain 
